Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Columbia researchers have used blockchain technology to build a system that can securely store, share, and analyze genetic and clinical data for precision medicine research.
A “loopy” discovery in bacteria is raising fundamental questions about the makeup of our own genome. And revealing a potential wellspring of material for new genetic therapies.
Director of the National Cancer Institute, Harold Varmus, MD'66, talked about the challenges and goals of precision medicine's efforts to tackle cancer.
Kevin L. Gardner, MD, PhD, has been named senior vice chair of the Department of Pathology and Cell Biology and professor of pathology and cell biology.